SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

19 May 2025 Evaluate
A fair growth of 18.60% in the revenue at Rs. 4047.70 millions was reported in the March 2025 quarter as compared to Rs. 3413.00 millions during year-ago period.The Net Profit of the company registered a slight decline of -22.88% to Rs. 304.70  millions from Rs. 395.10 millions.Operating profit for the quarter ended March 2025 rose to 1377.20 millions as compared to 997.80 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 4047.70 3413.00 18.60 16977.50 14867.10 14.20 16977.50 14867.10 14.20
Other Income 167.50 203.90 -17.85 355.10 348.30 1.95 355.10 348.30 1.95
PBIDT 1377.20 997.80 38.02 5220.60 4886.50 6.84 5220.60 4886.50 6.84
Interest 531.60 288.90 84.01 2202.40 574.20 283.56 2202.40 574.20 283.56
PBDT 845.60 708.90 19.28 3018.20 4312.30 -30.01 3018.20 4312.30 -30.01
Depreciation 433.80 291.40 48.87 1817.70 1023.90 77.53 1817.70 1023.90 77.53
PBT 411.80 417.50 -1.37 1200.50 3288.40 -63.49 1200.50 3288.40 -63.49
TAX 107.10 22.40 378.13 426.60 291.20 46.50 426.60 291.20 46.50
Deferred Tax 22.00 -60.00 -136.67 206.80 -285.20 -172.51 206.80 -285.20 -172.51
PAT 304.70 395.10 -22.88 773.90 2997.20 -74.18 773.90 2997.20 -74.18
Equity 136.20 136.00 0.15 136.20 136.00 0.15 136.20 136.00 0.15
PBIDTM(%) 34.02 29.24 16.38 30.75 32.87 -6.44 30.75 32.87 -6.44

Eris Lifesciences Share Price

1432.95 -13.55 (-0.94%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×